The morcellation controversy heats up as physicians all over the world who use Ethicon power morcellators are being asked to return the medical devices.
Earlier this year, Johnson & Johnson’s Ethicon unit suspended sales and distribution of its power morcellators. J&J is now calling for “a worldwide market withdrawal” of any Ethicon morcellation devices, and they are asking their customers-physicians and hospitals-to return any and all of these devices that have already been purchased. The company is issuing a credit for all devices returned before December 30, 2014. (
to see the letter.)
J&J’s decision comes after the FDA has recommended that the use of these devices be suspended until further review of the risk of these devices inadvertently spreading an unknown cancer in women with fibroids.
"Due to this continued uncertainty, Ethicon believes that a market withdrawal of Ethicon morcellation devices is the appropriate course of action at this time until further medical guidelines are established and/or new technologies are developed to mitigate the risk," the company said in an e-mailed statement to Reuters, as reported in this Huffington Post article.
How will this impact your practice, and what do you think about this recall?
(We invite you to share your thoughts in the Comment Section below.)
Tailored hormone therapy improves postoperative endometriosis outcomes
October 3rd 2024A recent study suggests that postoperative endometriosis patients experience improved quality of life through hormone therapies guided by optimizing treatment based on individual hormonal receptor profiles.
Read More
Family history criteria used to predict breast cancer genetic risk variants
September 26th 2024In a recent study, patients with a positive response to the Seven-Question Family History Questionnaire were more likely to present with a pathogenic or likely pathogenic variant in the BRCA1 and BRCA2 genes.
Read More
Study reports reduced SSI odds after gynecologic surgery from metronidazole and cefazolin
September 19th 2024A recent study shows that adding metronidazole to cefazolin significantly lowers the risk of surgical site infections in gynecologic cancer surgeries, enhancing patient outcomes.
Read More